Hypoxia Rewires RNA Methylation to Drive Pancreatic Neuroendocrine Tumor Growth

Deep inside a growing tumor, conditions can turn punishingly inhospitable. Blood vessels fail to keep pace with rapidly dividing cells, oxygen levels plummet, and the tumor is forced to adapt or die. Now, a team of researchers in China has mapped one of the molecular escape routes that pancreatic neuroendocrine neoplasms, an increasingly diagnosed class of tumors arising from hormone-producing cells of the pancreas, use to thrive under this low-oxygen stress. Their work, published in Cellular and Molecular Life Sciences, reveals an unexpected link between the tumor’s oxygen supply and a chemical tagging system that governs the fate of messenger RNA, the molecular intermediaries that carry genetic instructions from DNA to the cell’s protein-building machinery.

The tagging system in question is N6-methyladenosine, abbreviated m6A, the most abundant internal chemical modification found in the messenger RNA of higher organisms. Far from being a decorative flourish, m6A acts as a master regulator of RNA metabolism, influencing nearly every step of an RNA molecule’s life: how it is processed, exported from the nucleus, translated into protein, and ultimately degraded. The modification is installed by a writer complex whose core components include the enzymes METTL3 and WTAP, removed by eraser proteins, and interpreted by reader proteins such as IGF2BP3, which can stabilize methylated transcripts and protect them from destruction. Because m6A touches so many aspects of gene regulation, disruptions to this system have been implicated in a wide range of human cancers, making it one of the most intensely studied frontiers in molecular oncology.

What has remained murky, the researchers note, is how tumors balance the methylation and demethylation of their RNA when oxygen becomes scarce, and what the consequences of that balance are for pancreatic neuroendocrine neoplasms specifically. These tumors, often abbreviated pNENs, have attracted growing clinical attention because their incidence has been rising, yet the molecular drivers of their proliferation and spread remain incompletely understood. The new study set out to close that gap by examining what happens to m6A levels in pNEN cells exposed to hypoxic conditions that mimic the interior of a solid tumor.

The answer came quickly and dramatically. When pNEN cells were placed under hypoxia, the team documented a significant reduction in overall m6A levels, and the magnitude of this loss correlated with the advancement of the disease. In other words, the more the RNA methylation landscape was eroded by low oxygen, the more aggressive the tumors became. This observation framed a central mechanistic question: what molecular chain of events connects an environmental cue, the lack of oxygen, to a chemical change on RNA, and finally to the malignant behavior of the cell?

The first link in the chain proved to be a protein called USP38, a deubiquitinase whose normal job is to remove ubiquitin tags from other proteins and thereby shield them from degradation. The researchers found that hypoxia suppresses USP38 in pNEN cells. With USP38 out of the picture, two critical members of the m6A writer machinery, METTL3 and WTAP, became vulnerable to ubiquitination, the cellular process that flags proteins for destruction by the proteasome. Stripped of their protective deubiquitinase, METTL3 and WTAP were degraded, and the cell’s capacity to install m6A marks on its messenger RNA collapsed. It is an elegant example of biological economy: rather than shutting down the methylation enzymes one by one, the hypoxic tumor cell removes their bodyguard and lets the cell’s own waste-disposal system do the work.

With the writer complex disabled, the downstream consequences unfolded through a reader protein. The reduction in m6A modification, the study found, was mediated through IGF2BP3, one of the best-characterized m6A readers. IGF2BP3 typically binds methylated transcripts and prolongs their survival, so when methylation levels fall, its stabilizing grip loosens. The critical target transcript in this case was the messenger RNA encoding TGFBI, a secreted matrix protein whose name derives from transforming growth factor beta-induced. Under hypoxic conditions, the loss of m6A marks led to decreased stability of TGFBI mRNA, meaning the transcript was degraded faster and less TGFBI protein was produced. Hypoxia, in effect, was turning down the volume on a specific gene through an RNA-level mechanism rather than by altering the gene itself.

What makes this finding particularly striking is what TGFBI does next. The researchers demonstrated that TGFBI binds directly to Integrin beta 1, a cell-surface receptor that anchors cells to their surrounding matrix and transmits signals inward, and that TGFBI normally exerts a negative regulatory effect on ITGB1. When hypoxia drives TGFBI down, that brake is released. Integrin beta 1 expression rises in the pNEN cells, and with it comes activation of the Integrin/FAK signaling pathway, a canonical axis in which focal adhesion kinase relays cues from the cell surface to the interior, fueling proliferation, survival, motility, and metastatic behavior. The tumor cell, starved of oxygen, effectively rewires its own adhesion and signaling apparatus to grow faster and spread further.

Taken together, the pathway described by the team runs like a relay: hypoxia silences USP38, which permits the ubiquitination and destruction of METTL3 and WTAP; methylation of RNA falls; IGF2BP3 loses its hold on TGFBI mRNA, which destabilizes; TGFBI protein declines; Integrin beta 1 is released from repression; and the Integrin/FAK pathway surges, driving the proliferation and metastasis that define aggressive pNEN progression. Each node in this cascade is a potential point of intervention, and the authors suggest that their findings offer novel therapeutic targets for a tumor type that has long lacked precision options. Blocking the degradation of the writer complex, stabilizing TGFBI, or dampening Integrin/FAK signaling could each, in principle, sever the chain that links oxygen deprivation to malignancy.

The study also contributes to a broader conceptual shift in cancer biology. For decades, tumor research focused on mutations in DNA, permanent changes in the genetic code that drive cancer. Work like this underscores that the chemical decoration of RNA, which is dynamic and reversible, constitutes an equally powerful regulatory layer that tumors can manipulate in response to their environment. Hypoxia is one of the most universal stresses in solid tumors, and the discovery that it can reprogram the m6A landscape of pancreatic neuroendocrine neoplasms adds a mechanistic bridge between a well-known feature of the tumor microenvironment and the epitranscriptomic machinery that executes the cell’s adaptive response. It also explains why tumors that experience chronic oxygen deprivation may behave so differently from their well-oxygenated counterparts, even when their genomes are otherwise similar.

For patients with pancreatic neuroendocrine neoplasms, the clinical significance of these findings could be considerable. Current treatments, including surgery, somatostatin analogs, targeted agents, and peptide receptor radionuclide therapy, are effective for many but fall short in advanced disease. A validated understanding of the hypoxia-m6A-TGFBI-Integrin/FAK axis offers a molecular map for developing diagnostics, since m6A levels or TGFBI abundance could potentially serve as biomarkers of tumor aggressiveness, and for designing drugs that interrupt the pathway at its most vulnerable links. The work was supported by the National Natural Science Foundation of China, the Natural Science Foundation of Jiangsu Province, and other regional funding bodies, and it was conducted with institutional ethical approval for both animal studies and the use of discarded human tumor tissue. As with all mechanistic laboratory research, translating these findings into bedside applications will require further validation, but the study provides something increasingly rare and valuable in oncology: a complete, coherent chain of cause and effect running from the air a tumor breathes to the genes it expresses and the damage it ultimately inflicts.

Subject of Research: How hypoxia regulates m6A RNA methylation of TGFBI to activate Integrin/FAK signaling in pancreatic neuroendocrine neoplasms

Article Title: Hypoxia down-regulates METTL3 and WTAP activating Integrin/FAK signaling through m6A/IGF2BP3 dependent manners in TGFBI mRNA to promote pancreatic neuroendocrine neoplasms progression

Article References: Liu, P., Lu, F., Hu, C., Chen, J., Han, X., Bao, J., Sun, W., Xu, Y., Zhou, G., Yang, X., Chen, F., & Ye, M. (2026). Hypoxia down-regulates METTL3 and WTAP activating Integrin/FAK signaling through m6A/IGF2BP3 dependent manners in TGFBI mRNA to promote pancreatic neuroendocrine neoplasms progression. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06452-2

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06452-2

Keywords: pancreatic neuroendocrine neoplasms, hypoxia, m6A methylation, METTL3, WTAP, IGF2BP3, TGFBI, Integrin/FAK pathway, USP38, RNA modification, cancer metastasis, tumor microenvironment